Insider Trading November 19, 2026 09:31 PM

CervoMed CEO John Alam Buys $152,621 in Company Stock

The purchase comes as shares trade near a 52-week low, with the company also reporting clinical and manufacturing updates.

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
CRVO

John J. Alam, CEO and President of CervoMed Inc. (NASDAQ:CRVO), acquired 100,000 shares for $152,621 on November 18, 2026, at prices between $1.514 and $1.53. The stock now trades at $1.33, down 21% over the past week and close to its 52-week low of $1.27. Following the transactions, Alam beneficially owns 1,584,078 shares, including shares held jointly with his spouse, Dr. Sylvie Gregoire, and shares in individual retirement accounts. CervoMed recently presented Phase 2a data for neflamapimod, received a reiterated Buy rating and $25 price target from H.C. Wainwright, and announced a new 50mg oral tablet formulation of the drug.

CervoMed CEO John Alam Buys $152,621 in Company Stock
CRVO
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • CEO John J. Alam purchased 100,000 shares for $152,621 at prices between $1.514 and $1.53, increasing his beneficial ownership to 1,584,078 shares.
  • The stock is trading at $1.33, down 21% over the past week and near its 52-week low of $1.27, while InvestingPro analysis suggests the stock appears undervalued.
  • CervoMed reported Phase 2a trial data for neflamapimod showing a reduction in neurofilament light chain levels and announced a new 50mg tablet formulation, with H.C. Wainwright reiterating a Buy rating and $25 price target.

John J. Alam, chief executive officer and president of CervoMed Inc. (NASDAQ:CRVO), who also serves as a director and a 10% owner, acquired company shares valued at $152,621 on November 18, 2026. The purchases were executed through open-market transactions, with prices ranging from $1.514 to $1.53 per share. Alam bought 23,681 shares at $1.514 and an additional 76,319 shares at $1.53, for a total of 100,000 shares.

The stock currently trades at $1.33, down 21% over the past week, and is now trading near its 52-week low of $1.27. According to InvestingPro analysis, the stock appears undervalued at current levels, with the platform’s Fair Value estimate suggesting potential upside. InvestingPro offers 15 additional tips for CRVO, providing deeper insights into the company’s financial health and market position.

Following these transactions, Alam beneficially owns 1,584,078 shares of CervoMed common stock. This total includes 1,471,578 shares held jointly with his spouse, Dr. Sylvie Gregoire, PharmD., who is also a member of CervoMed’s Board of Directors. Additionally, 112,500 shares are held in the John J. Alam Roth IRA, and 12,500 shares are held indirectly through the Sylvie Gregoire Roth IRA.

In other recent developments, CervoMed presented initial data from its Phase 2a trial of neflamapimod, showing a reduction in mean plasma levels of neurofilament light chain over the first 12 weeks of treatment. The data was shared at the 15th International Society of Frontotemporal Dementias Annual Meeting in Philadelphia. H.C. Wainwright has reiterated a Buy rating on CervoMed stock with a $25.00 price target, highlighting the importance of these clinical trial results.

Additionally, CervoMed announced advancements in its drug development program, including a new 50mg oral tablet formulation of neflamapimod. These advancements allow for a higher-dose, twice-daily regimen, supported by the FDA’s removal of a previous plasma drug exposure limit. The controlled manufacturing process implemented by CervoMed is designed to ensure reproducible, large-scale tablet production. H.C. Wainwright also maintained its Buy rating following these announcements, indicating confidence in the company’s progress.

Risks

  • The stock is trading near its 52-week low of $1.27 and has declined 21% over the past week, indicating significant recent price weakness.
  • The clinical trial data is initial and from a Phase 2a trial, and the new tablet formulation and regulatory changes may not lead to successful commercialization.
  • InvestingPro’s Fair Value estimate and the analyst’s $25 price target are opinions and may not be realized, especially given the current market price.

More from Insider Trading

United Therapeutics EVP Mahon Offloads $4.69 Million in Stock Under 10b5-1 Plan Nov 19, 2026 NexPoint Director Offloads $56,750 in Stock as Shares Hover Near 52-Week Low Nov 19, 2026 NexPoint Residential CFO Paul Richards Buys $14,740 in Company Stock Nov 19, 2026 Kinetik Director ISQ Global Fund II Offloads $1.78 Million in Stock Nov 19, 2026 Tempus AI CFO Offloads $446,087 in Stock to Cover Tax Obligations Nov 19, 2026